ICPT Intercept Pharmaceuticals Inc

 

As filed with the Securities and Exchange Commission on November 20, 2023

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

 

FORM 15 

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 001-35668

 

 

INTERCEPT PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter) 

 

 

305 Madison Avenue

Morristown, NJ 07960

(646) 747-1000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) 

 

 

   Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)		x
Rule 12g-4(a)(2)		¨
Rule 12h-3(b)(1)(i)		x
Rule 12h-3(b)(1)(ii)		¨
Rule 15d-6		¨
Rule 15d-22(b)		¨

 

   Approximate number of holders of record as of the certification or notice date: One (1).

 

 

 

   Pursuant to the requirements of the Securities Exchange Act of 1934, Intercept Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 20, 2023

 

INTERCEPT PHARMACEUTICALS, INC.
By:	/s/ Michele Cera
Name:	Michele Cera
Title:	Executive Director

 

 

---